EuropaBio – the European bioindustries association – welcomes the work of the European Parliament’s Temporary Committee, over the last year. Despite today’s rejection of the final report (Fiori report), EuropaBio would like to welcome the year - long debate on human genetics and medicine. EuropaBio considers that this discussion was fruitful, in that it allowed for a full examination of the issues, some of which have great implications for the future of medical research and society.

There is no doubt that some of the issues discussed were about the future ethical framework in which Europe should undertake research into medicines and therapies. For the time being, these issues pose too many dilemmas to be solved in the context of one report.

"We very much welcome the open pluralistic debate on ethics and fully appreciate the challenges surrounding the Temporary Committee’s work in attempting to put together a balanced report that is supportive of science and medicine while respecting societal values. We look forward to contributing to the ongoing debate, which is legitimate and necessary," says Hugo Schepens, Secretary General of EuropaBio.

EuropaBio represents 40 corporate members operating worldwide and 17 national biotechnology associations (totalling nearly 1000 SMEs) involved in research and development, testing, manufacturing and distribution of biotechnology products. EuropaBio, the voice of European bioindustries, aims to be a promoting force for biotechnology and to present its proposals to industry, politicians, regulators, NGOs, and the public at large.